XL‑protein Launches Spin-Off PASylANTA Therapeutics to Develop Long‑Acting IL‑1Ra Biobetters
XL‑protein GmbH today announced the launch of PASylANTA Therapeutics GmbH, a new Germany-based biotechnology company focused on the development of long‑acting IL‑1 receptor antagonist (IL‑1Ra) therapies to support improved long‑term disease management.
PASylANTA builds on XL‑protein’s proprietary PASylation® technology, a biodegradable alternative